3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Classical hematology
1
Conditions
Venous Thromboembolism
22
Neoplasms
9
Pulmonary Embolism
6
Venous Thrombosis
5
Thrombosis
4
Multiple Myeloma
3
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Upper Extremity Deep Vein Thrombosis
1
Thromboembolism
1
Thrombocytopenia
1
Thrombocythemia, Essential
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Ovarian Neoplasms
1
Neoplasms, Plasma Cell
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Mesenteric Ischemia
1
Lymphoma
1
Leukemia
1
Intracranial Thrombosis
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Glioma
1
Glioblastoma
1
Endometrial Neoplasms
1
Embolism
1
Catheter-Related Infections
1
Astrocytoma
1
Interventions
fludarabine phosphate
12
Cyclophosphamide
12
Peripheral Blood Stem Cell Transplantation
10
Busulfan
8
Whole-Body Irradiation
7
Cyclosporine
7
Tacrolimus
6
Mycophenolic Acid
6
Antilymphocyte Serum
6
Methotrexate
5
Melphalan
4
Filgrastim
4
Etoposide
4
Flow Cytometry
3
fludarabine
2
Transplantation
2
Thiotepa
2
Radiotherapy
2
Polymerase Chain Reaction
2
Methylprednisolone
2
Cytogenetic Analysis
2
Cytarabine
2
Cyclosporins
2
Cord Blood Stem Cell Transplantation
2
Aspirin
2
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
2
tipifarnib
1
apixaban
1
aldesleukin
1
X-Rays
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Thrombocythemia, Essential
×
apixaban
×
Classical hematology
×
Clear all
NCT04243122
2024-05-29
AIRPORT-MPN
Ottawa Hospital Research Institute
Phase 2
Completed
44 enrolled